The global high potency active pharmaceutical ingredients (HPAPIs) market is projected to grow at an impressive rate during the forecast period. HPAPIs market is dramatically increasing as the R&D work on biological molecules uses for many therapies is gaining pace. The rising burden of cancer diseases and the growing demand for advanced treatments drive the growth of the HPAPIs market. HPAPIs are the fastest-growing market segment in the pharmaceutical industry. Highly potent drugs are increasingly prevalent in the drug development pipeline, driven by oncology research and more targeted therapies across several indications. Many pharmaceutical companies are investing in the production of HPAPI compounds. Meanwhile, these drugs represent a significant risk when handling, which may restrain the market growth.
The major players in the high potency active pharmaceutical ingredients (HPAPIs) market include Lonza, Novartis International AG, BASF AG, Carbogen Amcis AG, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Bristol-Myers Squibb, Pfizer Inc., Roche Diagnostics, Hospira Inc., Boehringer Ingelheim, Covidien Plc, Merck & Co., Bayer AG, Sigma-Aldrich Corporation, Sanofi Aventis.
Market Segmentation
By Product
- Synthetic
- Biotech
By Manufacturer
- In-House
- Outsourced
By Drug Type
- Innovative
- Generic
By Application
- Oncology
- Hormonal
- Glaucoma
- Others
The high potency active pharmaceutical ingredients (HPAPIs) market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa.
Naira Shekhawat has been into Content Writing just after completing her Graduation in English Literature. Her love for words has won her many accolades in her respective jobs ever since. Naira covers business sections for VMR News. She is a traveller by heart and loves writing on food blogs as a freelancer.